Literature DB >> 6975678

C1q binding activity in the sera of patients with chronic lung diseases.

K M Cooper, M Moore, A M Hilton.   

Abstract

Sera from patients with chronic lung diseases were tested for the presence of immune complexes (ICs) by the 125I-C1q-binding assay. Contrary to earlier reports, modification of the test system by addition of heparin decreased rather than increased the ability of the test to discriminate between control and pathological sera. Using the unmodified system, elevated C1q-binding activity (C1qBA) was found in patients with asthma (18%), chronic bronchitis (18%), sarcoidosis (18%), fibrosing alveolitis (50%), bronchogenic carcinoma (52%) and bronchiectasis (67%). Studies with the reducing agent 2-mercaptoethanol (2-ME) suggested a role for IgM rheumatoid factor (RF) and/or IgG-containing complexes in the C1q-reactive material of sera from patients with bronchiectasis and bronchogenic carcinoma. In the latter two groups, C1qBA was found to correlate with serum levels of IgG and IgA but not with C3 and C4. A weak condition between levels of C-reactive protein (CRP) and C1qBA was found in the bronchogenic carcinoma group. Carcinoembryonic antigen (CEA) levels were elevated in all groups studied but no correlation with C1qBA was demonstrated, suggesting that CEA and CEA-ICs, if present, do not have an influence on the C1qBA of such sera. The results indicate that elevated serum C1qBA is a concomitant of both chronic inflammatory and neoplastic diseases of the lung but the extent of any similarity in the non-immunoglobulin components of the immune complexes in the respective conditions remains unknown.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975678      PMCID: PMC1537240     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Dissociation of human serum macroglobulins.

Authors:  H F DEUTSCH; J I MORTON
Journal:  Science       Date:  1957-03-29       Impact factor: 47.728

2.  Effect of chemical and enzymatic radioiodination on in vitro human Clq activities.

Authors:  C Heusser; M Boesman; J H Nordin; H Isliker
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

3.  Immunological abnormalities in bronchiectasis with chronic bronchial suppuration.

Authors:  A M Hilton; L Doyle
Journal:  Br J Dis Chest       Date:  1978-07

Review 4.  Detection of immune complexes in human diseases.

Authors:  R H Zubler; P H Lambert
Journal:  Prog Allergy       Date:  1978

5.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

6.  Circulating immune complexes in patients with lung neoplasms.

Authors:  A Tincani; G Balestrieri; A T Moraschini; A Fadini; G Tassi; C Rugarli
Journal:  Ric Clin Lab       Date:  1980 Apr-Jun

7.  Incidence of circulating immune complexes in patients with lung cancer and their effect on antibody-dependent cytotoxicity.

Authors:  C Gropp; K Havemann; T Scherfe; W Ax
Journal:  Oncology       Date:  1980       Impact factor: 2.935

8.  Correlation of elevated C1q binding activity and carcinoembryonic antigen levels with clinical features and prognosis in bronchogenic carcinoma.

Authors:  P B Dent; J A Louis; P B McCulloch; C W Dunnett; J C Cerottini
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

9.  Pretreatment, prediagnosis immunoglobulin, and alpha 1-antitrypsin levels in patients with bronchial carcinoma.

Authors:  D R Nash; J W McLarty; N G Fortson
Journal:  J Natl Cancer Inst       Date:  1980-04       Impact factor: 13.506

10.  Are circulating CEA immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract?

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640

View more
  3 in total

1.  Cutaneous vasculitis and immune complexes in severe bronchiectasis.

Authors:  A M Hilton; P S Hasleton; A Bradlow; B C Leahy; K M Cooper; M Moore
Journal:  Thorax       Date:  1984-03       Impact factor: 9.139

2.  Reactivity of low molecular weight material in cellular immune complex assays.

Authors:  K M Cooper; M Moore
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

3.  Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.

Authors:  Daniel Ajona; Cristina Razquin; Maria Dolores Pastor; Maria Jose Pajares; Javier Garcia; Felipe Cardenal; Michael Fleischhacker; Maria Dolores Lozano; Javier J Zulueta; Bernd Schmidt; Ernest Nadal; Luis Paz-Ares; Luis M Montuenga; Ruben Pio
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.